Source: Radiotherapy and Oncology. Unidade: FMRP
Subjects: NEOPLASIAS PULMONARES, NEOPLASIAS PULMONARES, ENSAIO CLÍNICO, DOSAGEM DE RADIAÇÃO
ABNT
ARRUDA, Gustavo Viani e GOUVEIA, Andre G. e MORAES, Fabio Y. In reply to Li et al. Letter to the editor. “Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): a meta-analysis of randomized clinical trials.”. [Carta]. Radiotherapy and Oncology. Clare: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.radonc.2022.09.017. Acesso em: 08 out. 2025. , 2022APA
Arruda, G. V., Gouveia, A. G., & Moraes, F. Y. (2022). In reply to Li et al. Letter to the editor. “Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): a meta-analysis of randomized clinical trials.”. [Carta]. Radiotherapy and Oncology. Clare: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.radonc.2022.09.017NLM
Arruda GV, Gouveia AG, Moraes FY. In reply to Li et al. Letter to the editor. “Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): a meta-analysis of randomized clinical trials.”. [Carta] [Internet]. Radiotherapy and Oncology. 2022 ; 177 245-246.[citado 2025 out. 08 ] Available from: https://doi.org/10.1016/j.radonc.2022.09.017Vancouver
Arruda GV, Gouveia AG, Moraes FY. In reply to Li et al. Letter to the editor. “Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): a meta-analysis of randomized clinical trials.”. [Carta] [Internet]. Radiotherapy and Oncology. 2022 ; 177 245-246.[citado 2025 out. 08 ] Available from: https://doi.org/10.1016/j.radonc.2022.09.017